Advantages of Migrating to Electronic R&D

Michael Elliott of Atrium Research and Consulting looks at the advantages of migrating from paper records to an all-electronic format in R&D. Article

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.